Stellar Biotechnologies Announces Joint Research on Clostridium Difficile Immunotherapy Accepted for Presentation
(firmenpresse) - PORT HUENEME, CA -- (Marketwired) -- 07/24/13 -- (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that a preclinical abstract on KLH-conjugate vaccine for Clostridium difficile infection ("C. diff") has been accepted for oral presentation at the 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClostPath 8) to be held in Queensland, Australia October 22-26, 2013.
ClostPath is the preeminent scientific conference in the field of clostridial pathogenesis and covers the latest discoveries presented by leading international researchers.
The abstract titled "An Anti-C. difficile PSII Polysaccharide-KLH Conjugate Vaccine is Efficacious in Mice" is the result of preclinical research conducted together by scientists from Stellar and the University of Guelph (Ontario, Canada) ("Guelph"). The abstract highlights data that suggest that a PSII polysaccharide conjugated to Keyhole Limpet Hemocyanin (KLH) may be effective in stimulating immunity against Clostridium difficile infection.
Stellar and Guelph are working together under research and license option arrangements forged last year around the two groups' shared interest in developing novel, non-antibiotic methods to treat the devastating C. diff infection.
Clostridium difficile is a major and growing cause of mortality and morbidity in hospitalized patients. Incidence of C. diff is at a record high in the U.S. with more than 330,000 cases reported in 2009. C. diff is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. It causes severe diarrhea and life-threatening intestinal conditions such as colitis. The cost of C. diff related treatment in the U.S. and Europe is estimated at more than $7 billion annually.
(TSX VENTURE: KLH) (OTCQB: SBOTF) (FRANKFURT: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of
Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.
Herbert Chow, Ph.D.
Chief Technology Officer
Phone +1 (805) 488-2800
Frank Oakes
Chairman
MZ Group
Mark A. McPartland
Senior Vice President
Phone: +1 (212) 301-7130
Web:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.07.2013 - 16:01 Uhr
Sprache: Deutsch
News-ID 1248570
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PORT HUENEME, CA
Phone:
Kategorie:
Healthcare
Anmerkungen:
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Stellar Biotechnologies Announces Joint Research on Clostridium Difficile Immunotherapy Accepted for Presentation
"
steht unter der journalistisch-redaktionellen Verantwortung von
Stellar Biotechnologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
